Loading clinical trials...
Loading clinical trials...
Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial
Conditions
Interventions
GTX-104
Nimotop 30 MG Oral Capsule
Locations
22
United States
The University of Alabama at Birmingham
Birmingham, Alabama, United States
Brain and Spine Neurological Institute
Phoenix, Arizona, United States
Community Regional Medical Center
Fresno, California, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
Emory University School of Medicine Emergency Neurosciences
Atlanta, Georgia, United States
Northwestern Feinberg Pavillion Neuro and Spine ICU
Chicago, Illinois, United States
Start Date
October 20, 2023
Primary Completion Date
December 1, 2024
Completion Date
December 1, 2024
Last Updated
October 1, 2024
NCT07160088
NCT07307508
NCT07149922
Lead Sponsor
Grace Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions